TNYA

0.28663.99%
BR

Bruce R. Conklin

Scientific Founder

Dr. Bruce R. Conklin, M.D., serves as Senior Investigator at the Gladstone Institute of Cardiovascular Disease. Dr. Conklin is the Founder of the widely used public resources, BayGenomics, GenMAPP and WikiPathways. He is a Scientific Founder of Tenaya Therapeutics, Inc. He has appointments in the Departments of Medicine and Cellular & Molecular Pharmacology and the Division of Medical Genetics at the University of California, San Francisco. Dr. Conklin consults for several leading biotechnology companies. He served as an Associate Director of the General Clinical Research Center at San Francisco General Hospital from 1995 to 2001. He serves as a Member of the Scientific Advisory Board at iPierian, Inc. He serves as a Member of Scientific Advisory Board of The Assay Depot, Inc. (formerly known as Scientist).He serves as Member of Science Advisory Board at Assay Depot, Inc. Dr. Conklin serves as a Member of Advisory board at Alitora Systems, Inc. Dr. Conklin served as a Member of the Advisory Board of Assay Depot, Inc. since September 2008. He served as a Member of Scientific Advisory Board at Shrink Nanotechnologies, Inc. since October 2009. Dr. Conklin was the Founding Director of Gladstone Genomics Core. He founded the Gladstone Genomics and Stem Cell Cores. Dr. Conklin is the Associate Director of the Gladstone CIRM Scholars Training Program. He is a Co-Chairman of the UCSF-California Academy of Sciences Affiliation Task Force. He was a Co-Chairman of the UCSF public science project since 2004. He is the Founding Director of the Gladstone Stem Cell Core. Dr. Conklin is a Member of several honorary societies including the American Society for Clinical Investigation. He is a Professor of Genomic Medicine at the University of California, San Francisco. He is the recipient of a CIRM New Stem Cell Lines grant. Dr. Conklin received an A.B. degree in public health from the University of California, Berkeley in 1982. He completed an MD degree at Case Western Reserve University in Cleveland in 1988. During his last two years of medical school, Dr. Conklin had the privilege of working under the tutelage of Nobel Laureate Julius Axelrod, Ph.D., at the National Institutes of Health. He then completed his residency at Johns Hopkins Hospital, a postdoctoral fellowship in the laboratory of Henry Bourne, MD at UCSF and postdoctoral training in molecular pharmacology at UCSF.

Positions